Recent studies show that HIV patients are 10 to 20 times more likely to develop lymphoma compared to individuals without HIV.

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The Billings Firefighters Stairclimb Team is hosting a charity event at Diamond X Brewing to support the Leukemia & Lymphoma ...

Most major sections of the new animal drug application for Laverdia-CA1 have been deemed complete by the FDA, bringing the ...

Nancy Pelosi just made Tempus AI (TEM) the stock of the moment. The former Speaker of the House quietly purchased 50 call ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...